Skip to main content

Advertisement

SpringerLink
Log in

Non-polymer drug-eluting coronary stents

  • Review Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

Cardiovascular complications are leading causes of most fatalities. Coronary artery disease and surgical failures contribute to the death of the majority of patients. Advanced research in the field of medical devices like stents has efficiently resolved these problems. Clinically, drug-eluting stents have proven their efficacy and safety compared to bare metal stents, which have problems of in-stent restenosis. However, drug-loaded stents coated with polymers have shown adverse effects related to the stability and deterioration of the polymer coating over time. This results in late stent thrombosis and immunogenicity. These reasons laid the foundation for the development of non-polymeric drug-eluting stents. This review focuses on non-polymer drug-eluting stents loaded with different drugs like anti-inflammatory agents, anti-thrombotic, anti-platelet agents, immune suppressants and others. Surface modification techniques on stents like crystalline coating; microporous, macroporous, and nanoporous coatings; and chemically modified self-assembled monolayers are described in detail. There is also an update on clinically approved products and those under development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, et al. Percutaneous coronary intervention in the current era compared with 1985–1986. Circulation. 2000;102(24):2945–51.

    Article  PubMed  CAS  Google Scholar 

  2. Berger E, Williams DO, Reinert S, Most AS. Sustained efficacy of percutaneous transluminal coronary angioplasty. Am Heart J. 1986;111(2):233–6.

    Article  PubMed  CAS  Google Scholar 

  3. Block PC. Percutaneous transluminal coronary angioplasty. Am J Roentgenol. 1980;135(5):955–9.

    Article  CAS  Google Scholar 

  4. Holmes DR. State of the art in coronary intervention. Am J Cardiol. 2003;91(3):50–3.

    Article  Google Scholar 

  5. Khan W, Farah S, Domb AJ. Drug eluting stents: developments and current status. J Control Release. 2012;161(2):703–12.

    Article  PubMed  CAS  Google Scholar 

  6. Thipparaboina R, Khan W, Domb AJ. Eluting combination drugs from stents. Int J Pharm. 2013;454(1):4–10.

    Article  PubMed  CAS  Google Scholar 

  7. Marx SO, Marks AR. Bench to bedside. Circulation. 2001;104:852–5.

    Article  PubMed  CAS  Google Scholar 

  8. Simard T, Hibbert B, Ramirez FD, Froeschl M, Chen Y-X, O'Brien ER. The evolution of coronary stents: a brief review. Can J Cardiol. 2014;30(1):35–45.

    Article  PubMed  Google Scholar 

  9. Park KW, Kang S-H, Velders MA, Shin D-H, Hahn S, Lim W-H, et al. Safety and efficacy of everolimus-versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. American heart journal. 2013;165(2):241–50. e4

    Article  PubMed  CAS  Google Scholar 

  10. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393–402.

    Article  PubMed  CAS  Google Scholar 

  11. Sammel AM, Chen D, Jepson N. New generation coronary stent technology—is the future biodegradable? Heart Lung Circ. 2013;22(7):495–506.

    Article  PubMed  Google Scholar 

  12. Flores-Rios X, Marzoa-Rivas R, Abugattas-de Torres JP, Pinon-Esteban P, Aldama-Lopez G, Salgado-Fernandez J, et al. Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients. Am Heart J. 2008;155(4):648–53.

    Article  PubMed  CAS  Google Scholar 

  13. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368(3):254–65.

    Article  PubMed  CAS  Google Scholar 

  14. Garg S, Magro M, Serruys P. 6.627-drug-eluting stents. 2011. https://www.mysciencework.com/publication/show/e1b8681a25377b47df4f54aee8b604bf.

  15. Jonner M, Finn A, Farb A, Mont E. Pathology of drug-eluting stents in humans. J Am Coll Cardiol. 2006;48:193–202.

    Article  Google Scholar 

  16. Prabhu S, Hossainy S. Modeling of degradation and drug release from a biodegradable stent coating. J Biomed Mater Res A. 2007;80(3):732–41.

    Article  PubMed  CAS  Google Scholar 

  17. Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev. 2001;48(2):229–47.

    Article  PubMed  CAS  Google Scholar 

  18. Rossi F, Casalini T, Raa E, Masi M, Perale G. Bioresorbable polymer coated drug eluting stent: a model study. Mol Pharmaceutics. 2012;9(7):1898–910.

    Article  CAS  Google Scholar 

  19. Huang Y, Ng HCA, Ng XW, Subbu V. Drug-eluting biostable and erodible stents. J Control Release. 2014;193:188–201.

    Article  PubMed  CAS  Google Scholar 

  20. Abizaid A, Costa JR. New drug-eluting stents. Circulation: Cardiovasc Interv. 2010;3(4):384–93.

    CAS  Google Scholar 

  21. Costa JR, Caixeta A, Abizaid AA. Novel drug-eluting stent systems. Interv Cardiol : Princ Pract. 2017:368–76.

  22. Seo J, Lee J, Na K. Polymeric materials for drug release system in drug eluting stents. J Pharm Investig. 2016;46(4):317–24.

    Article  CAS  Google Scholar 

  23. Bartorelli AL, Trabattoni D, Fabbiocchi F, Montorsi P, MARTINI SD, CALLIGARIS G, et al. Synergy of passive coating and targeted drug delivery. J Interv Cardiol. 2003;16(6):499–505.

    Article  PubMed  Google Scholar 

  24. Acharya G, Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev. 2006;58(3):387–401.

    Article  PubMed  CAS  Google Scholar 

  25. Tsujino I, Ako J, Honda Y, Fitzgerald PJ. Drug delivery via nano-, micro and macroporous coronary stent surfaces. Expert Opin Drug Deliv. 2007;4(3):287–95.

    Article  PubMed  CAS  Google Scholar 

  26. Ma X, Wu T, Robich MP. Drug-eluting stent coatings. 2012.

  27. Swetha M, Sahithi K, Moorthi A, Srinivasan N, Ramasamy K, Selvamurugan N. Biocomposites containing natural polymers and hydroxyapatite for bone tissue engineering. Int J Biol Macromol. 2010;47(1):1–4.

    Article  PubMed  CAS  Google Scholar 

  28. Grube E, Gerckens U, Müller R, Büllesfeld L. Drug eluting stents: initial experiences. Z Kardiol. 2002;91:44–8.

    Article  PubMed  CAS  Google Scholar 

  29. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death. Cancer. 2000;88(11):2619–28.

    Article  PubMed  CAS  Google Scholar 

  30. Sriram V, Patterson C. Cell cycle in vasculoproliferative diseases. Circulation. 2001;103(19):2414–9.

    Article  PubMed  CAS  Google Scholar 

  31. Kauffman RF, Singh JP. Inventors; Local delivery of dipyridamole for the treatment of proliferative diseases patent US5314688A. 1994.

  32. Peters S, Behnisch B, Heilmann T, Richter C. First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents. J Renin-Angiotensin-Aldosterone Syst. 2009;10(2):91–5.

    Article  PubMed  CAS  Google Scholar 

  33. Deuse T, Erben RG, Ikeno F, Behnisch B, Boeger R, Connolly AJ, et al. Introducing the first polymer-free leflunomide eluting stent. Atherosclerosis. 2008;200(1):126–34.

    Article  PubMed  CAS  Google Scholar 

  34. Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Polymer-free sirolimus-and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease clinical perspective. Circulation. 2011;124(5):624–32.

    Article  PubMed  CAS  Google Scholar 

  35. Watt J, Kennedy S, McCormick C, Agbani EO, McPhaden A, Mullen A, et al. Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model. Catheter Cardiovasc Interv. 2013;81(4):698–708.

    Article  PubMed  Google Scholar 

  36. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, et al. Polymer-free biolimus A9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model clinical perspective. Circulation: Cardiovasc Interv. 2010;3(2):174–83.

    CAS  Google Scholar 

  37. Naber CK, Urban P, Ong PJ, Valdes-Chavarri M, Abizaid AA, Pocock SJ, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a leaders free ACS sub-study. Eur Heart J. 2017;38(13):961–9.

    PubMed  Google Scholar 

  38. Mani G, Johnson DM, Marton D, Feldman MD, Patel D, Ayon AA, et al. Drug delivery from gold and titanium surfaces using self-assembled monolayers. Biomaterials. 2008;29(34):4561–73.

    Article  PubMed  CAS  Google Scholar 

  39. Morice M-C, Bestehorn H-P, Carrié D, Macaya C, Aengevaeren W, Wijns W, et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention: J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol. 2006;2(1):45–52.

    Google Scholar 

  40. Deconinck E, Sohier J, De Scheerder I, Van den Mooter G. Pharmaceutical aspects of drug eluting stents. J Pharm Sci. 2008;97(12):5047–60.

    Article  PubMed  CAS  Google Scholar 

  41. Adriaenssens T, Mehilli J, Wessely R, Ndrepepa G, Seyfarth M, Wieczorek A, et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent?: results of the ISAR-PEACE randomized trial. J Am Coll Cardiol. 2007;49(12):1265–71.

    Article  PubMed  CAS  Google Scholar 

  42. Costa JR Jr, Abizaid A, Feres F, Costa R, Seixas AC, Maia F, et al. EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention: j EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol. 2008;4(1):53–8.

    Article  Google Scholar 

  43. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616):899–907.

    Article  PubMed  CAS  Google Scholar 

  44. Tamburino C, Di Salvo ME, Capodanno D, Capranzano P, Parisi R, Mirabella F, et al. Real world safety and efficacy of the Janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the tacrolimus-eluting stent (TEST) registry. Catheter Cardiovasc Interv. 2009;73(2):243–8.

    Article  PubMed  Google Scholar 

  45. Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol. 2004;44(7):1363–7.

    PubMed  CAS  Google Scholar 

  46. Liu X, De Scheerder I, Desmet W. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis. Expert Rev Cardiovasc Ther. 2004;2(5):653–60.

    Article  PubMed  CAS  Google Scholar 

  47. Song D, Hsu LF, Au JLS. Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci. 1996;85(1):29–31.

    Article  PubMed  CAS  Google Scholar 

  48. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent. Circulation. 2004;109(4):487–93.

    Article  PubMed  CAS  Google Scholar 

  49. Farah S, Khan W, Domb AJ. Crystalline coating of rapamycin onto a stent: process development and characterization. Int J Pharm. 2013;445(1):20–8.

    Article  PubMed  CAS  Google Scholar 

  50. Levy Y, Khan W, Farah S, Domb AJ. Surface crystallization of rapamycin on stents using a temperature induced process. Langmuir. 2012;28(15):6207–10.

    Article  PubMed  CAS  Google Scholar 

  51. Diaconu A, Balan V, P Chiriac A. Upon the developments of drug-eluting stents in the treatment of coronary lesions. Recent Pat Mater Sci 2013;6(3):229–237.

  52. Fajadet J. The Minvasys Amazonia PAX and Nile PAX polymer free paclitaxel eluting stent program. Proc TCT. 2009:21–5.

  53. Wu SZ, Harish S, Sanders-Millare D, Guruwaiya JA, Mirzaee D, Hossainy S et al. Inventors; Surface features of an implantable medical device patent US 6805898 B1. 2004.

  54. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005;26(15):1475–81.

    Article  PubMed  Google Scholar 

  55. Chen W, Habraken TC, Hennink WE, Kok RJ. Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjug Chem. 2015;26(7):1277–88.

    Article  PubMed  CAS  Google Scholar 

  56. Bassous N, Cooke JP, Webster TJ. Enhancing stent effectiveness with nanofeatures. Methodist DeBakey Cardiovasc J. 2016;12(3):163–8.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Mikhalovska L, Chorna N, Lazarenko O, Haworth P, Sudre A, Mikhalovsky S. Inorganic coatings for cardiovascular stents: in vitro and in vivo studies. J Biomed Mater Res B Appl Biomater. 2011;96(2):333–41.

    Article  PubMed  CAS  Google Scholar 

  58. Kang H-J, Kim DJ, Park S-J, Yoo J-B, Ryu Y. Controlled drug release using nanoporous anodic aluminum oxide on stent. Thin Solid Films. 2007;515(12):5184–7.

    Article  CAS  Google Scholar 

  59. Gultepe E, Nagesha D, Sridhar S, Amiji M. Nanoporous inorganic membranes or coatings for sustained drug delivery in implantable devices. Adv Drug Deliv Rev. 2010;62(3):305–15.

    Article  PubMed  CAS  Google Scholar 

  60. Beltran-Partida E, Valdez-Salas B, Moreno-Ulloa A, Escamilla A, Curiel MA, Rosales-Ibanez R, et al. Improved in vitro angiogenic behavior on anodized titanium dioxide nanotubes. J Nanobiotechnol. 2017;15(1):10.

    Article  CAS  Google Scholar 

  61. Stevenson CL, Santini JT, Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv Drug Deliv Rev. 2012;64(14):1590–602.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Martin F, Walczak R, Boiarski A, Cohen M, West T, Cosentino C, et al. Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release. 2005;102(1):123–33.

    Article  PubMed  CAS  Google Scholar 

  63. Y-l H, Wang S-l, Q-m J, Yu H-b, Wang B, Ma Y-y, et al. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chin Med J. 2007;120(7):552–6.

    Google Scholar 

  64. Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A, et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv. 2005;64(1):85–90.

    Article  PubMed  Google Scholar 

  65. Wang Y, Zhang W, Zhang J, Sun W, Zhang R, Gu H. Fabrication of a novel polymer-free nanostructured drug-eluting coating for cardiovascular stents. ACS Appl Mater Interfaces. 2013;5(20):10337–45.

    Article  PubMed  CAS  Google Scholar 

  66. Bhargava B, Reddy NK, Karthikeyan G, Raju R, Mishra S, Singh S, et al. A novel paclitaxel-eluting porous carbon–carbon nanoparticle coated, nonpolymeric cobalt–chromium stent: evaluation in a porcine model. Catheter Cardiovasc Interv. 2006;67(5):698–702.

    Article  PubMed  Google Scholar 

  67. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–47.

    Article  PubMed  CAS  Google Scholar 

  68. Worthley SG, Abizaid A, Kirtane AJ, Simon DI, Windecker S, Brar S, et al. First-in-human evaluation of a novel polymer-free drug-filled stent: angiographic, IVUS, OCT, and clinical outcomes from the RevElution study. J Am Coll Cardiol Intv. 2017;10(2):147–56.

    Article  Google Scholar 

  69. Ruan C-M, Bayer T, Meth S, Sukenik CN. Creation and characterization of n-alkylthiol and n-alkylamine self-assembled monolayers on 316L stainless steel. Thin Solid Films. 2002;419(1):95–104.

    Article  CAS  Google Scholar 

  70. Mani G, Chandrasekar B, Feldman MD, Patel D, Agrawal C. Interaction of endothelial cells with self-assembled monolayers for potential use in drug-eluting coronary stents. J Biomed Mater Res B Appl Biomater. 2009;90(2):789–801.

    Article  PubMed  CAS  Google Scholar 

  71. Mani G, Torres N, Oh S. Paclitaxel delivery from cobalt-chromium alloy surfaces using self-assembled monolayers. Biointerphases. 2011;6(2):33–42.

    Article  PubMed  CAS  Google Scholar 

  72. Mirmohseni A, Hosseini J, Shojaei M, Davaran S. Design and evaluation of mixed self-assembled monolayers for a potential use in everolimus eluting coronary stents. Colloids Surf B: Biointerfaces. 2013;112:330–6.

    Article  PubMed  CAS  Google Scholar 

  73. Balakrishnan B, Dooley JF, Kopia G, Edelman ER. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J Control Release. 2007;123(2):100–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2):121–36.

    Article  PubMed  CAS  Google Scholar 

  75. Hwang C-W, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104(5):600–5.

    Article  PubMed  CAS  Google Scholar 

  76. Bozsak F, Chomaz J-M, Barakat AI. Modeling the transport of drugs eluted from stents: physical phenomena driving drug distribution in the arterial wall. Biomech Model Mechanobiol. 2014;13(2):327–47.

    Article  PubMed  Google Scholar 

  77. Commandeur S, VAN BEUSEKOM HM, VAN DER GIESSEN WJ. Polymers, drug release, and drug-eluting stents. J Interv Cardiol. 2006;19(6):500–6.

    Article  PubMed  Google Scholar 

  78. Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymer-free paclitaxel-coated Zilver PTX stents—evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol. 2011;22(5):603–10.

    Article  PubMed  Google Scholar 

  79. Urban P, Abizaid A, Chevalier B, Greene S, Meredith I, Morice M-C, et al. Rationale and design of the LEADERS FREE trial: a randomized double-blind comparison of the BioFreedom drug-coated stent vs the gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J. 2013;165(5):704–9.

    Article  PubMed  CAS  Google Scholar 

  80. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005;25(4):748–53.

    Article  PubMed  CAS  Google Scholar 

  81. Naseerali C, Hari P, Sreenivasan K. The release kinetics of drug eluting stents containing sirolimus as coated drug: role of release media. J Chromatogr B. 2010;878(7):709–12.

    Article  CAS  Google Scholar 

  82. Gallo A, Mani G. A stent for co-delivering paclitaxel and nitric oxide from abluminal and luminal surfaces: preparation, surface characterization, and in vitro drug release studies. Appl Surf Sci. 2013;279:216–32.

    Article  CAS  Google Scholar 

  83. Kamberi M, Nayak S, Myo-Min K, Carter TP, Hancock L, Feder D. A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: insight to the drug release mechanisms. Eur J Pharm Sci. 2009;37(3):217–22.

    Article  PubMed  CAS  Google Scholar 

  84. Guideline IHT. Stability testing: photostability testing of new drug substances and products. Q1B, Current Step. 1996;4.

  85. Klick S, Muijselaar P, Waterval J, Eichinger T, Korn C, Gerding TK, et al. Stress testing of drug substances and drug products. Pharm Technol. 2005;29(2):48–66.

    Google Scholar 

  86. Guideline IHT. Bracketing and matrixing designs for stability testing of new drug substances and products Q1D. Finalized guideline: February. 2002.

  87. Rudd DR. Suitability of analytical methods for stability testing-is there room for improvement? J Validation Technols. 1999;5:255–61.

    Google Scholar 

  88. Glomme A, Marz J, Dressman J. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J Pharm Sci. 2005;94(1):1–16.

    Article  PubMed  CAS  Google Scholar 

  89. Carrie D, Berland J, Verheye S, Hauptmann KE, Vrolix M, Violini R, et al. A multicenter randomized trial comparing amphilimus-with paclitaxel-eluting stents in de novo native coronary artery lesions. J Am Coll Cardiol. 2012;59(15):1371–6.

    Article  PubMed  CAS  Google Scholar 

  90. Abizaid A, editor. PAX A trial (Amazonia PAX versus TAXUS Liberté): 4-month follow-up: IVUS and optical coherence tomography evaluation. EuroPCR annual meeting; 2010.

  91. Iofina E, Langenberg R, Blindt R, Kühl H, Kelm M, Hoffmann R. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol. 2006;98(8):1022–7.

    Article  PubMed  CAS  Google Scholar 

  92. Rhydwen GR, Webster MW, Ruygrok PN, Ormiston JA, O'Shaughnessy B, Stewart JT. Preliminary experience with the V-Flex Plus coronary stent: immediate and one-month clinical outcome. Catheter Cardiovasc Interv. 1999;47(4):504–8.

    Article  PubMed  CAS  Google Scholar 

  93. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J. 2009;30(8):923–31.

    Article  PubMed  CAS  Google Scholar 

  94. Dang Q, Li Y, Gao L, Jin Z, Gou L. Six-month angiographic and one-year clinical outcomes of polymer free paclitaxel-eluting stent in patients with ST-segment elevation myocardial infarction: a comparison with permanent polymer sirolimus-eluting stent. Chin Med J. 2012;125(19):3393–7.

    PubMed  Google Scholar 

  95. Zhang R, Zhang Q, Zhu J, Chen L, Zhang C, Zhou X, et al. Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry. Chin Med J. 2011;124(21):3521.

    PubMed  CAS  Google Scholar 

  96. Costa J.. VESTAsync (MIV therapeutics) program update. Transcatheter Cardiovascular Therapeutics. 2012.

  97. Costa JR, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. J Am Coll Cardiol Intv. 2009;2(5):422–7.

    Article  Google Scholar 

  98. Seth A, Center NDI, editors. Nanoparticle Based Stents–FOCUS np™(Envision Scientific) program update. 23rd Transcatheter Cardiovascular Therapeutics (TCT) Conference. Miami, FL, USA; 2012.

  99. Garot P, Morice M-C, Tresukosol D, Pocock SJ, Meredith IT, Abizaid A, et al. 2-year outcomes of high bleeding risk patients after polymer-free drug-coated stents. J Am Coll Cardiol. 2017;69(2):162–71.

    Article  PubMed  Google Scholar 

  100. Costa RA, Abizaid A, Abizaid AS, Garcia dBB, Berland J, Petrov I, et al. Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial. EuroIntervention: J EuroPCR Collab Working Group Interv Cardiol Eur Soc Cardiol. 2012;7(11):1301–9.

    Article  Google Scholar 

  101. Yu M, Xu B, Kandzari DE, Wu Y, Yan H, Chen J, et al. First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial. Catheter Cardiovasc Interv. 2014;83(3):405–11.

    Article  PubMed  Google Scholar 

  102. Massberg S, Byrne R, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Intracoronary stenting and angiographic results: test efficacy of sirolimus-and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) investigators. Polymer-free sirolimus-and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the intracoronary stenting and angiographic results: test efficacy of sirolimus and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) trial. Circulation. 2011;124(5):624–32.

    Article  PubMed  CAS  Google Scholar 

  103. Godino C, Chiarito M, Donahue M, Testa L, Colantonio R, Cappelletti A, et al. Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer rEgistry). Int J Cardiol. 2017;231:54–60.

    Article  PubMed  Google Scholar 

  104. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47(1):175–81.

    Article  PubMed  Google Scholar 

  105. Legutko J, Zasada W, Kaluza GL, Heba G, Rzeszutko L, Jakala J, et al. A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study). Indian Heart J. 2013;65(4):388–94.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Romaguera R, Brugaletta S, Gomez-Lara J, Pinar E, Jimenez-Quevedo P, Gracida M, et al. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus. Catheter Cardiovasc Interv. 2015;85(4):E116–E22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Nagavendra Kommineni and Raju Saka have equal contribution.

Authors and Affiliations

  1. Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India

    Nagavendra Kommineni, Raju Saka & Wahid Khan

  2. School of Pharmacy-Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel

    Abraham J. Domb

Authors
  1. Nagavendra Kommineni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raju Saka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wahid Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abraham J. Domb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wahid Khan or Abraham J. Domb.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kommineni, N., Saka, R., Khan, W. et al. Non-polymer drug-eluting coronary stents. Drug Deliv. and Transl. Res. 8, 903–917 (2018). https://doi.org/10.1007/s13346-017-0414-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-017-0414-3

Keywords

Search

Navigation